Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2010

Biovail and MedGenesis Receive $2.1M Grant for Parkinson Disease Trials

  • Biovail and MedGenesis Therapeutix confirmed the receipt of $2.1 million from the Michael J. Fox Foundation to fund further clinical development of glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson disease.

    GDNF is a naturally occurring growth factor that protects and promotes the survival of dopamine-producing nerve cells, the firms explain. The candidate is being developed by Biovail and MedGenesis through a collaboration agreement announced in January. Parkinson disease is the first GDNF indication the partnership is focused on.

    The GDNF co-development agreement followed on from MedGenesis’ negotiation of an exclusive, worldwide license to the GDNF protein from Amgen for both CNS and non-CNS applications. This deal, also announced in January, gave Amgen a small equity stake in MedGenesis.

    .   



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »